NYSEAMERICAN:TRXCTransEnterix Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for TransEnterix.

TransEnterix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransEnterix.

TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its earnings results on Thursday, May, 14th. The medical instruments supplier reported ($0.41) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.12. The medical instruments supplier earned $0.60 million during the quarter, compared to the consensus estimate of $0.54 million. View TransEnterix's earnings history.

1 brokers have issued 1-year target prices for TransEnterix's shares. Their forecasts range from $1.00 to $1.00. On average, they expect TransEnterix's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 188.2% from the stock's current price. View analysts' price targets for TransEnterix.

News coverage about TRXC stock has been trending neutral this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TransEnterix earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the next few days. View the latest news about TransEnterix.

TransEnterix saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 2,160,000 shares, a decrease of 10.7% from the May 31st total of 2,420,000 shares. Based on an average daily volume of 2,640,000 shares, the short-interest ratio is presently 0.8 days. Approximately 5.0% of the company's stock are short sold. View TransEnterix's Current Options Chain.

Some companies that are related to TransEnterix include Omega Diagnostics Group (ODX), Daxor (DXR), Daxor (DXR), IsoRay (ISR), IsoRay (ISR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV), Akers Biosciences (AKR), Relevium Technologies (RLV), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), Ansell (ANSLF), ANSELL LTD/S (ANSLY) and Commerzbank (CZMWY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Opko Health (OPK).

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TRXC stock can currently be purchased for approximately $0.35.

TransEnterix has a market capitalization of $17.99 million.

The official website for TransEnterix is www.transenterix.com.

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.